Niagen Bioscience, Inc. (NAGE) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
NAGE currently has 79.9M outstanding shares. with minimal authorized share overhang for future dilution. The company has minimally diluted shareholders by 6.07% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 06, 2026 |
10-Q filing | 79.9M shares outstanding |
80M | 0 |
| Aug 06, 2025 |
10-Q filing | 79.2M shares outstanding |
79M | 0 |
| May 07, 2025 |
10-Q filing | 77.8M shares outstanding |
78M | 0 |
| Mar 04, 2025 |
10-K filing | 78.1M shares outstanding |
78M | 0 |
| Oct 31, 2024 |
10-Q filing | 76.0M shares outstanding |
76M | 940K |
| Aug 07, 2024 |
10-Q filing | 75.6M shares outstanding |
76M | 1.4M |
| May 08, 2024 |
10-Q filing | 75.2M shares outstanding |
75M | 1.7M |
| Mar 06, 2024 |
10-K filing | 75.0M shares outstanding |
75M | 1.9M |
| Nov 08, 2023 |
10-Q filing | 75.1M shares outstanding |
75M | 1.9M |
| Aug 09, 2023 |
10-Q filing | 75.0M shares outstanding |
75M | 1.9M |
| Jun 22, 2023 |
S-3 filing: This is an S-3 filing for a mixed shelf offering including debt securities, warrants, common stock, and units comprised of the aforementioned securities. They are also registering a $47.8 million ATM offering of common stock with B. Riley Securities, Inc. and Raymond James & Associates, Inc. as sales agents. |
75M | 2.1M |
| May 10, 2023 |
10-Q filing | 74.8M shares outstanding |
75M | 2.1M |
| Mar 08, 2023 |
10-K filing | 69.7M shares outstanding |
70M | 7.2M |
| Nov 03, 2022 |
S-3 filing: This S-3 filing is for the offer and resale of up to 2,480,000 shares of common stock by selling stockholders. |
68M | 8.6M |
| Nov 02, 2022 |
10-Q filing | 68.3M shares outstanding |
68M | 6.1M |
| Oct 11, 2022 |
8-K filing: ChromaDex, Inc. entered into an amended and restated supply agreement with Société des Produits Nestlé SA, and a securities purchase agreement for NHSc to purchase 3,816,794 shares of the company's common stock for $5 million. ($5.0M proceeds) |
68M | 6.1M |
| Aug 10, 2022 |
10-Q filing | 68.3M shares outstanding |
68M | 6.1M |
| May 12, 2022 |
10-Q filing | 68.3M shares outstanding |
68M | 6.1M |
| Mar 14, 2022 |
10-K filing | 67.2M shares outstanding |
67M | 7.2M |
| Nov 03, 2021 |
10-Q filing | 68.2M shares outstanding |
68M | 6.2M |
| Aug 03, 2021 |
10-Q filing | 68.0M shares outstanding |
68M | 6.4M |
| May 06, 2021 |
10-Q filing | 67.7M shares outstanding |
68M | 6.7M |
| Mar 23, 2021 |
S-3 filing: This S-3 filing relates to the resale of common stock by a selling stockholder, EverFund, who may sell up to 3,846,153 shares. The company will not receive any proceeds from the sale of these shares. |
67M | 7.7M |
| Mar 12, 2021 |
10-K filing | 66.7M shares outstanding |
67M | 3.8M |
| Feb 25, 2021 |
8-K filing: ChromaDex Corporation closed a private placement on February 23, 2021, issuing 3,846,153 shares of its Common Stock to EverFund at a price of $6.50 per share, for gross proceeds of $25.0 million. ($25.0M proceeds) |
62K | 71M |
| Nov 04, 2020 |
10-Q filing | 0.1M shares outstanding |
62K | 71M |
| Aug 06, 2020 |
10-Q filing | 0.1M shares outstanding |
61K | 71M |
| Jun 12, 2020 |
S-3 filing: This is an S-3 filing. The company is registering shares of common stock for potential sale under a shelf registration. |
61M | 9.1M |
| May 21, 2020 |
S-3 filing: This S-3 filing relates to the offering of common stock by selling stockholders. The company will not receive any proceeds from the sale of these shares. |
61M | 9.1M |
| May 18, 2020 |
10-Q filing | 61.5M shares outstanding |
61M | 0 |
| Mar 10, 2020 |
10-K filing | 59.8M shares outstanding |
60M | 0 |